Oxaliplatin (NSC 266046)

For research use only.

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

111 publications

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Oxaliplatin (NSC 266046) has been cited by 111 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 MkTKSpVv[3Srb36gRZN{[Xl? NFjN[IM{OC9zMEFCpO69VQ>? M3jLe|E3yqCq M{fQTmROW09? MWPhZ5RqfmG2ZYOgUpJnOg>? Mn3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2  NV3VSXVmTnWwY4Tpc44hSXO|YYm= NYHVbFVCOy9zMD:zNEDPxE1? MlizNVYhcA>? MYjEUXNQ NUmzb4c{cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? M2jOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2  M2D4eWZ2dmO2aX;uJGF{e2G7 NEPidHU{OMLizszN M2\xeVI1KGh? NHfiXJhFVVOR NFjpZZNqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? NUnZfXZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVY1OTVpPkK0OVU3PDF3PD;hQi=>
SW620 M1zOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHnWnZ5OTBvN{CgcYcwVA>? MVuyOE81QC95MjDo NIXKNoZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2NkOwOUc,OjR4NE[zNFU9N2F-
SW480  NI\vd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPkclhMPDhiaNMg MVzJR|UxRTJyLkigeYcwdUx? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{ME[3OUc,OjR5MkC2O|U9N2F-
HCT116 NF;QR4FHfW6ldHnvckBCe3OjeR?= MXKyM|UhyrWP Ml\BNlQwPDhiaB?= Mlzmd5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36= MoDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkG0NVEoRjJ2N{[xOFEyRC:jPh?=
HT-29 NFPxZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHyNeKh|ryP M32yelAuPzJiaB?= NHnS[FVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NY\0OWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PUUVHDqM7:TR?= MmHoNE04OiCq M1v5NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MmTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFzLkOwxsDDucLiMT6wNkDPxE1? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HEK293 NYPaR4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjlSolKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= M2fKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HT-29 NFnEd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7qZVRjUUN3ME61NEDPxE1? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HCT-116 M1rNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXXRmhYUUN3ME22MlI1yqEEsdMgNk46PyEQvF2= NIXnVYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO|Q1QCd-MkWzNFc1PDh:L3G+
MCF-7 NU[5V2M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? M1njTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HepG2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULER5JKUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN M4iwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
A549 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTDeo1KSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN NYr3OFFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
SGC7901 M3rLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\NXWlEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?= Moe2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116  NF;2dGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorTO|IhcMLi Ml:3TWM2OD14LkKzxtExNjd3INM1[{9uVA>? MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkC2N|EoRjJ3M{[wOlMyRC:jPh?=
SW480 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTsT3I4OiCqwrC= M4nFR2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV|NkC2N|E9N2F-
MIAPaCa-2 M2rLVGZ2dmO2aX;uJGF{e2G7 MWeyOgKBkcL3TR?= NWTuNIo6OjRxNEigbC=> NWnpUFJCcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> MmD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1 MVnGeY5kfGmxbjDBd5NigQ>? NVPnNmlrOjYkgJpCuW0> NVfwc3F[OjRxNEigbC=> Mor4bY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|wrC= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
MIAPaCa-2 Mk\jRZBweHSxc3nzJGF{e2G7 MlrtNlXjiIoEtV2= NIey[pQzPCCq Mle5bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NVnmRo9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1 M13tc2Fxd3C2b4Ppd{BCe3OjeR?= NFT6N5gzPeLCidM1US=> MlvuNlQhcA>? NUnxRYhDcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
HPDE NUSwfIIzS2WubDDWbYFjcWyrdImgRZN{[Xl? NX2yVIljOjVxNUCg{txO M1vzSVI1NzR6IHi= MmPGbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
SW1990 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWmyOU82OCEQvF2= NEKzNmMzPC92ODDo MoixbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NIT3eZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
MIAPaCa-2 M2H0dGNmdGxiVnnhZoltcXS7IFHzd4F6 MnfzNlUwPTBizszN M37YVlI1NzR6IHi= MkP6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVeyOU82OCEQvF2= M3;vV|I1NzR6IHi= NIHOOFNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP NWL5WIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF6Lk[gxtEhOS5{IN88US=> NIXTTFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549 NIjXOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOyTWM2OD13LkigxtEhOC54IN88US=> M3PheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
SW480 MkTWSpVv[3Srb36gRZN{[Xl? MVKxNQKBkcL3Zz;tcC=> NYjSRpVlOjUkgJno NY\oNGh{\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NELNT|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620 MVXGeY5kfGmxbjDBd5NigQ>? MUCxNQKBkcL3Zz;tcC=> MljRNlTjiImq NGO0dWJmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= M2K4Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW480 MUfGeY5kfGmxbjDBd5NigQ>? NF6zXVAyOOLCidM1[{9udA>? NYDET2VXOjUkgJno NWHH[|hwcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= M17vNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620 NH7XZVhHfW6ldHnvckBCe3OjeR?= NE[wbVkyOOLCidM1[{9udA>? MXuyOQKBkWh? M1\vVolv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
HT-29 NXniflB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDkfHNYUUN3ME21MlIzKM7:TR?= MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
SNU-175 NVqxN|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD1zLkWxJO69VQ>? NHzBN2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
COLO-320DM M2q5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T1NmlEPTB;NT6zPEDPxE1? Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
DLD-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiwU2FKSzVyPUiuOlUh|ryP MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O|koRjJ3N{[xOFc6RC:jPh?=
DiFi NXnXXXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3sW|FOUUN3ME2xNE46PSEQvF2= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
HCT-15 M{HqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRThwNkSg{txO NFLyXVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1 NI[zU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXvTWM2OD1zNz61JO69VQ>? M4K4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
TMK-1 M33iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ{Lk[g{txO Mn\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
MKN-45 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLnTWM2OD1zND6wJO69VQ>? M1HZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
AGS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HPW2lEPTB;MUCuOkDPxE1? NHzqR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP4TWM2OD13Mz61JOKyKDFwNTFOwG0> M4fHSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OECxNFA4Lz5{NUiwNVAxPzxxYU6=
SiHa MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13XV2lEPTB;MD64JOKyKDBwMTFOwG0> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyMUCwO{c,OjV6MEGwNFc9N2F-
HT-29 NVzBSWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\STWM2OD1|NT62JO69VQ>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
DLD-1 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfoXGRKSzVyPUOyMlIh|ryP M{jJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN|A5PTxxYU6=
HT29 NYX1VodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnkXVZvUUN3ME22N{DPxE1iwsGgNVg> M2jjXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38 M1nsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDVZpKSzVyPUKzJO69VSEEsTCy NFzUT3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOFA5PCd-Mk[wNFQxQDR:L3G+
SW620 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP6VWFKSzVyPUOuOlgh|ryP M3L2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
SW480 M4XSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfwcZV7UUN3ME2yMlg3KM7:TR?= M3nmXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
RKO NVvjN21xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn6TWM2OD1zLkKzJO69VQ>? MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
LoVo MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi1VY1KSzVyPUGuNkDPxE1? MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
KM12 NYnMWHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TTfmlEPTB;ND6zO{DPxE1? M1nKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT116p53- M1;vPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILIWHJKSzVyPUGuNFgh|ryP MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116 NUnXPYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlGxTWM2OD1zLkC0JO69VQ>? M{XSflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT15 NWHuXlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX22UWFoUUN3ME2xMlQ{KM7:TR?= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HT29 NVrZcVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTDTWM2OD1{Lk[5JO69VQ>? NIDweWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
DLD1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMEGg{txO M3;l[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
Colo205 NFnvSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fyfmlEPTB;Mz6zN{DPxE1? Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE NFThXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNwM{Og{txO NWXsPZJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
CT26  MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXG0JI1O NXzicY5GPDhiaNMg NIDIU4ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= M4m5UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO|AyOjxxYU6=
CT26  MVvGeY5kfGmxbjDBd5NigQ>? Mo\BOEBuVQ>? NVXJZnNuPDhiaNMg M1TYZ4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3 NFKwVmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
CT26  MlO0SpVv[3Srb36gRZN{[Xl? NH3ldVk1KG2P NHrYUlI1QCCqwrC= NIO0SlRqdmS3Y3XzJIF2fG:yaHHnfS=> NFzZNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
SK-OV-3 NYDuRmtuTnWwY4Tpc44hSXO|YYm= MnmzOVAh|ryPwrC= NYnlO5p4PDhiaNMg MUTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NHXSN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 NEHON29HfW6ldHnvckBCe3OjeR?= MV6yNEDPxE4EoB?= MUWyOIg> NW\UfFU6eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 MUjGeY5kfGmxbjDBd5NigQ>? MmXQNVAh|ryPwrC= NWXjNGkyOjSq NYLITIc2eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> NH:yZ2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
SK-OV-3 MUTGeY5kfGmxbjDBd5NigQ>? MVe1NEDPxE1? MYG5OkBp NFzMVGt2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MnX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 MWTGeY5kfGmxbjDBd5NigQ>? NV6wbIxwOzBizszN NHjQ[481QGh? NWW1[IgyfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| NIXBV3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 NH3EWGxHfW6ldHnvckBCe3OjeR?= NYCxUVY1OTBizszNxsA> MV[0PIg> MYj1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
SK-OV-3 MlKySpVv[3Srb36gRZN{[Xl? M1jIeVUxKM7:TR?= MlnvPVYhcA>? M3L2W5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NE[yfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
OVCAR-5 MoHzSpVv[3Srb36gRZN{[Xl? NGOzRmg{OCEQvF2= NIKxNI01QGh? NWDkblRsfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ NHP4c|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 MmPySpVv[3Srb36gRZN{[Xl? MmH0NVAh|ryPwrC= MmPkNlRp NWf2clRifHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ MlzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3 NV\mVJBjS2WubDDWbYFjcWyrdImgRZN{[Xl? NV3UTmZsOC1zMECg{txO NHnlZlkzPC92OD:3NkBp M{jjZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
OVCAR-5 M1nIe2NmdGxiVnnhZoltcXS7IFHzd4F6 M1;Be|AuPjBizszN NXvZNYJFOjRxNEivO|IhcA>? M3LIVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NITNcHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
PA-1 NWr2ZoFPS2WubDDWbYFjcWyrdImgRZN{[Xl? NWi5VZJkOC1{MDFOwG0> M3S1VFI1NzR6IHi= MVzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M33iVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
HCT116 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\wTWM2OD1yLkSxxsDDucLiMD6wNkDPxE1? MmnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEi1PVYoRjJ4MUS4OVk3RC:jPh?=
HT29 M1TsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PiO2lEPTB;MD64POKhyrIEoECuNkDPxE1? NILib2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
SNU-387 NHrHeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ3wrFCteKhOi55IN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
SNU-475 NYmzS4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLCPXZKUUN3MP-8olMxKM7:TR?= MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
Hep-G2 NYTZOYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfwO|hKSzVyPUGzMlHDqMLzwrCxMlYh|ryP MoTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DN4RKSzVyPU[uOeKhyrIEoEGuNUDPxE1? NG\OWmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo  MYHGeY5kfGmxbjDBd5NigQ>? M3TKZVEwPSEQvF2= MV[yOE81QCCq MXfpcoR2[2W|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q NFGxbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
HCT116 p53+/+ NYTvVphGTnWwY4Tpc44hSXO|YYm= MlHZNU82KM7:TR?= NHvKTnkzPC92ODDo Ml36bY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
MDA-MB-231 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jDNGlEPTB;MkOuNUDDuSByLkGg{txO NFLtNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNVU6OSd-Mk[yNVE2QTF:L3G+
MCF-7 NGmycWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF3LkSgxtEhOC5|IN88US=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
SK-BR-3 M2DjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonMTWM2OD1|MT6wJOKyKDBwMTFOwG0> MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
LoVo MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfVfodIPDhiaNMg NVvoOm16UUN3ME25OE45OyEQvF2= M{jzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O|U6Lz5{NkK2PVc2QTxxYU6=
HCT116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M122b|Q5KGkEoB?= MV;JR|UxRTFzLki2JO69VQ>? M{j5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O|U6Lz5{NkK2PVc2QTxxYU6=
SW480 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrPelB3PDhiaNMg NHPQdmRKSzVyPUGuPFch|ryP NH7zSJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2PVc2QSd-Mk[yOlk4PTl:L3G+
CaES-17 NILqdXlEgXSxdH;4bYNqfHliQYPzZZk> NEjveHUx6oDVMU[wxsDPxE1? M{LXVFQ5yqCq MofxTWM2OD13LkZCpOKyyqByLkKg{txO MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
HKESC-2 MmD2R5l1d3SxeHnjbZR6KEG|c3H5 Mk\WNQKBmzF4MNMg{txO Mn75OFjDqGh? NH;xW41KSzVyPUWuPOKhyrIEoECuOUDPxE1? MkjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control


    (Only for Reference)
Animal Research:

[6]

- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
DMF Insoluble
Ethanol ''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
Synonyms L-OHP, Eloxatin
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah June 11 2020 Phase 1
NCT04003792 Recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 1 2020 Phase 2
NCT03800693 Recruiting Drug: Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin Malignant Digestive System Neoplasm Emory University|Hematology/Oncology Pharmacy Association|University of Pittsburgh March 14 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) supplier | purchase Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) cost | Oxaliplatin (NSC 266046) manufacturer | order Oxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID